Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program

Sep 18, 2026 · 08:08 AM ET· updated 1h ago

XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease,

Share
Why It Matters

XORTX plans to ask the FDA to test a new gout medicine soon. This is a normal step forward that shows the company is making progress on their drug.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
XRTX2.08
+0.42 (+25.42%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.